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ABSTRACT
A set of new sulfurated drug hybrids, mainly derived from caffeic and ferulic acids and rosmaricine, has
been synthesized and their ability to inhibit both STAT3 and NF-jB transcription factors have been eval-
uated. Results showed that most of the new hybrid compounds were able to strongly and selectively bind
to STAT3, whereas the parent drugs were devoid of this ability at the tested concentrations. Some of them
were also able to inhibit the NF-jB transcriptional activity in HCT-116 cell line and inhibited HCT-116 cell
proliferation in vitro with IC50 in micromolar range, thus suggesting a potential anticancer activity. Taken
together, our study described the identification of new derivatives with dual STAT3/NF-jB inhibitory activ-
ity, which may represent hit compounds for developing multi-target anticancer agents.
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Introduction
Activation or suppression of STAT signaling play important physio-
pathological roles in several human diseases (among which cardio-
vascular, atherosclerosis, rheumatoid arthritis, Alzheimer disease,
and particularly cancer).
Research over the last two decades has consolidated the con-
cept that there is a high correlation between tumor development
and inflammation: compounds of the inflammatory tumor micro-
environment include leukocytes, cytokines, complement compo-
nents, and are orchestrated by transcription factors, such as Signal
Transducer and Activator of Transcription 3 (STAT3) and nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-jB)1,2.
STATs are a family of latent, cytoplasmic transcription factors
that are able to regulate cell growth and survival by modulating
the expression of specific target genes. STAT3 was found to be
constitutively activated by aberrant upstream tyrosine kinase
activity in a broad spectrum of cancer cell lines and human
tumors, and it is considered a promising target for cancer ther-
apy3. All STAT proteins in mammals consist of six domains, as fol-
lows: N-domain (ND), coiled-coil, DNA binding, linker, Src
homology 2 (SH2), and transcriptional activation domain4.
Inhibitors exert their pharmacological effects by diverse mecha-
nisms such as blocking abnormally activated upstream kinases
such as JAK and Src or directly suppressing the STAT3 phosphoryl-
ation5. Most of the currently available inhibitors act by preventing
STAT3 tyrosine phosphorylation, i.e. they directly bind to the SH2
domain of STAT3 and prevent tyrosine phosphorylation, protein
dimerisation, and transcriptional activity6,7.
STAT3 can directly interact with nuclear factor, NF-jB family
member RelA, through acetyltransferase p300-mediated acetyl-
ation, trapping it in the nucleus and thereby contributing to con-
stitutive NF-jB activation in tumor-associated hematopoietic cells
and various malignancies7,8.
CONTACT Anna Sparatore anna.sparatore@unimi.it Department of Pharmaceutical Sciences, Universita degli Studi di Milano, Via L. Mangiagalli, 25-20133
Milano, Italy
 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distri-
bution, and reproduction in any medium, provided the original work is properly cited.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2017
VOL. 32, NO. 1, 1012–1028
https://doi.org/10.1080/14756366.2017.1350658
The NF-jB transcription factor family drives tumor progression
and metastasis in many cancers by regulating genes involved in
inflammation, cellular survival, and proliferation9–11. It is a protein
complex able to control DNA transcription and cytokine produc-
tion and therefore acting with a synergistic effect on cancer devel-
opment, inflammation, and breast cancer12,13.
A large number of natural and synthetic compounds, charac-
terised by very different chemical structures, have been described
to inhibit STAT3 through several pathways, and the development
of novel STAT3 inhibitors is still intensively pursued. Excellent
reviews summarise the acquisitions in this field4,14–20. Particularly
relevant for the present study are, the polyphenolic compounds21
(as epigallocatechin-3-gallate (EGCG)22, resveratrol23, curcumin24,25,
butein26, ellagic acid27, caffeic acid28, ferulic acid29, carnosic acid,
carnosol and related diterpenes30, celastrol31 and others) and dif-
ferent kinds of sulfurated compounds (a,b-unsaturated sulfones,
as stattic32; tosyl esters and amides as S3I-2016; dithiolethiones33,
methanethiosulfonates34; allicin and diallylpolysulfides35; isothio-
cyanates as sulfuraphane36; etc.), which are known to display
antiproliferative activity and/or cancer chemopreventive proper-
ties, through multiple mechanisms, including STAT3 and/or NF-jB
inhibition, either directly or indirectly. The inhibitory potencies
versus the relevant proteins are largely variable among the che-
motypes and in the different biological settings that are
considered.
Agents able to modulate multiple targets can be more effica-
cious and less prone to produce resistance than drugs that
address only a single target; therefore, molecules able to inhibit
(one or both) transcription factors by interfering with multiple
approaches to their activation pathways could represent useful
tools to treat cancer.
In particular, it has been recently demonstrated that dithiole-
thione derivatives, in addition to the antiangiogenic and tumor
suppressor PP2A activation properties37–39, inhibited NF-jB tran-
scriptional activity via a covalent reaction, leading to the formation
of a disulfide bond with the NF-jB p50 and p65 subunits to inhibit
DNA binding in human estrogen receptor–negative breast cancer
cells33.
Among diallylpolysulfides, diallyl trisulfide (DATS), a constituent
of processed garlic, inhibited phosphorylation, dimerisation, and
nuclear translocation of STAT3 in prostate cancer cells in culture
and in vivo35.
S-methyl methanethiosulfonate (SMMTS), isolated from cauli-
flower, is able to inhibit colon tumor incidence when administered
to rats during the post-initiation phase of carcinogenesis34 and 2-
((methylsulfonyl)thio)ethyl 2-propylpentanoate ACS33 (compound
a, Figure 1), exhibited in vitro good antiproliferative activity in
micromolar concentrations on different tumoral cell lines40,41 and
in vivo inhibited the growth of PC3 in subcutaneous xenografts40.
More recently, we have observed42,43 that some conjugated
molecules (a–i, Figure 1), incorporating the thiosulfonate function,
were able to strongly bind the STAT3-SH2 domain in vitro in an
AlphaScreen-based assay, with IC50s in the submicromolar-low
micromolar range, whereas the parent compounds were devoid of
this ability up to the maximum tested concentration (30lM). Thus,
the effected conjugation of the sulfurated and non-sulfurated moi-
eties strongly improved the low or faint affinity to STAT3 of one
or both parent compounds.
These compounds exhibited some selectivity for STAT3 inhib-
ition versus STAT1, despite the high degree (78%) of sequence
homology between the two STAT proteins.
Compounds a, c, d, and h showed a moderate antiproliferative
activity (MTT assay) on HCT-116 cells, with IC50 from 84 to 135 lM.
The other hybrids, as well as all the parent sulfurated and non-sul-
furated compounds were inefficacious on HCT-116 cells at concen-
tration up to 200 lM. Since the valuable STAT3 inhibition has
Figure 1. Structures of compounds a–i.
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been observed in a cell-free assay, the low correspondence
between STAT3 inhibition and cytotoxicity could be related to the
physicochemical properties of the compounds, which will require
optimisation.
On these bases, while attempting to improve the ADME charac-
teristics of the above compounds, we deemed interesting to
extend our investigation aimed at the identification of other sul-
furated hybrid molecules capable of direct inhibition of STAT3-SH2
domain and, possibly, of improving also the inhibitory activity ver-
sus the NF-jB transcription factor that may be simultaneously pre-
sent in one or both of the parent compounds44.
To this purpose, we chose to conjugate several sulfurated moi-
eties (the formerly used and a few others containing different
kinds of linking functions) with two phenolic acids (as ferulic and
caffeic) and one basic cathecol derivative as rosmaricine, leaving
free in all cases the hydroxyl groups to preserve their antioxidant
potentiality.
The capability of phenolic acids, particularly caffeic acids and
its arylalkyl esters, to interact with STAT3 and NF-jB transcription
factors and to exert antiproliferative/antitumoral activity, versus
several tumor cell lines in in vitro culture and subcutaneous xeno-
grafts, is largely documentated28,45–47.
Phenolic antioxidants, besides acting as scavengers for reactive
oxygen intermediates (ROIs, representing signaling molecules to
activate NF-jB pathway), may also, for instance, inhibit NF-jB DNA
binding. In some settings, caffeic acid inhibited STAT3 with IC50s
in the range 70–100 lM, while its phenylethyl and phenyl propyl
esters displayed IC50s in the range 15–30 lM and the improved
activity is, at least in part, related to the improved lipophilicity.
On the other hand, rosmaricine is an aminoditerpene, structur-
ally related to carnosic acid, carnosol, and rosmanol, which are
endowed with antioxidant, radical scavenger, and antiproliferative
activities, through mechanisms that involve, among others, NF-jB
and STAT3 inhibition48–50. Rosmaricine is obtained from dry leaves
of Rosmarinus officinalis L. treated with ammonia in the presence
of air. It is formed through a complex reaction between some oxi-
dation derivatives of carnosic acid and the ammonia used to liber-
ate the alkaloids supposed to be present in the plant51. We have
chosen rosmaricine, rather than other phenolic diterpenoids, in
the context of a general pharmacological investigation of this
unusual molecule, going on since long time52,53.
In order to evaluate the contribution of the antioxidant activity
of the free phenolic groups to the inhibition of transcription
factors, some hybrid molecules of non-hydroxylated or variously
substituted cinnamic acids were also considered (cinnamic, 3,4-
dichlorocinnamic, 3,4-dimethoxycinnamic and 3,4-bis((2-methoxye-
thoxy)methoxy)cinnamic acids). On the other hand, to evidence
the significance of the reactive thiosulfonate function for STAT3
inhibition, the 5-(methylsulfonylthio)pentanoic acid was compared
with the structurally close 5-(methylsulfonyl)pentanoic acid, con-
taining the unreactive sulfone group.
The sulfurated conjugated molecules, together with the parent
compounds (Figures 2 and 3) were submitted to the
AlphaScreen–based assay54 to investigate their ability to interact
with STAT3-SH2 domain. Moreover, the cytotoxicity (MTT assay)55
of these compounds on HCT-116 cell line (a human colon carcin-
oma, which express high level of STAT356) was also evaluated. The
most active compounds were also submitted to the Luciferase
assay57,58, to measure their ability to inhibit NF-jB promoter and
STAT3 reporter activity in HCT-116 and HeLa cells, respectively.
Materials and methods
General
All commercially available solvents and reagents were used with-
out further purification, unless otherwise stated; CC¼ flash column
chromatography; melting points (uncorrected) were determined
with a B€uchi apparatus. 1H-NMR and 13C-NMR spectra were
recorded with a Bruker DRX Avance 200MHz (Bruker Italia, Srl,
Milano, Italy) or with a Varian 300MHz Oxford spectrometer
(Varian, Palo Alto, CA) equipped with a non-reverse probe at 25
C, in CDCl3 or DMSO-d6, acetone-d6, D2O; the chemical shifts were
expressed in ppm (d), coupling constants (J) in Hertz (Hz). High-
resolution mass spectra (HRMS) was performed on a FT-Orbitrap
mass spectrometer (Thermo Scientific, Milano, Italy) in positive or
negative electrospray ionization (ESI). UPLC-MS analysis: ACQUITY
UPLC BEH C18 column, 130 Å, 1.7mm, 2.1mm 50 mm (Waters,
Switzerland) and Xevo G2-XS Q-TOF with electrospray ionization
source (Waters, Switzerland). MaxEnt 1 software : used to deconvo-
lute the multiple charge states. Microwave reactor: BiotageVR initi-
ator classic (Biotage, Uppsala, Sweden).
The known sulfurated starting compounds 159, 360, 561, 662,
963, 1163, and the ferulic and caffeic acid methyl esters 1364 and
2065 have been synthesised according to the literature
procedures.
Sulfurated compounds
S-4-hydroxybutyl methanesulfonothioate (2)
Sodium methanethiosulfonate (1.9 g, 14.37mmol) and 4-bromobu-
tanol (2.0 g, 13.07mmol) were mixed together in anhydrous DMF
(7ml) under inert atmosphere (Scheme 1). The reaction was stirred
at 60 C for 5 h and was monitored by thin layer chromatography
(TLC). After this time, inorganic salts were filtered and the solution
was evaporated under reduced pressure. The resulting dark-yellow
oil was purified by CC (silica gel; CH2Cl2/MeOH; in gradient); the
product eluted with 0.3% of MeOH. A light brown oil was
obtained. Yield: 19%. 1H-NMR (300MHz, DMSO-d6): d¼ 4.45 (br s,
1H, OH collapsed with D2O), 3.48 (s, 3H, CH3), 3.42 (t, 2H,
J¼ 8.7 Hz, CH2OH), 3.19 (t, 2H, J¼ 6.9 Hz, SCH2), 1.76-1.66 (m, 2H,
Figure 2. Structures of the investigated sulfurated moieties.
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Figure 3. Structures of the investigated derivatives of ferulic, caffeic, and other cinnamic acids and of rosmaricine.
Scheme 1. Reagents and conditions: (a) DMF, N2, 60 C, 5 h; (b) DMSO, N2, 60 C, 5 h; (c) dry DMF, 60 C, 5 h.
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CH2), 1.52–1.43 (m, 2H, CH2) ppm.
13C-NMR (75MHz, CDCl3):
d¼ 62.0, 50.9, 36.4, 31.3, 26.3. HRMS (ESI) m/z Calcd for C5H13O3S2
[MþH]þ: 185.03061; found: 185.03010.
2-(Allyldisulfanyl)ethanol (4)
2-Mercaptoethanol (1.24 g; 0.016mol) was added to a solution of
diallyl disulfide (0.803 g; 0.0055mol) in DMSO (5ml) and the mix-
ture was stirred at 50 C for 5 h under a N2 stream. The solution
was purified by flash chromatography on silica gel, using cyclohex-
ane/ethyl acetate (68:32) as eluent. A colorless oil was obtained.
Yield: 50%. 1H-NMR (300MHz, CDCl3): d¼ 5.92–5.78 (m, 1H),
5.26–5.16 (m, 2H), 3.87 (t, J¼ 5.86 Hz, 2H), 3.34 (d, J¼ 7.33Hz, 2H),
2.85 (t, J¼ 5.86Hz, 2H), 1.88 (s, 1H, collapses with D2O). 13C-NMR
(75MHz, CDCl3): d¼ 133.2, 118.7, 60.2, 42.1, 41.2 ppm. GC/MS (HP
5973; EI): m/z 150 [Mþ].
Methyl 5-((methylsulfonyl)thio)pentanoate (7)
To a solution of 5-(methylsulfonylthio)pentanoic acid (22, 250mg,
1.18mmol), DCC (243mg, 1.18mmol) and DMAP (13.2mg,
0.12mmol) in anhydrous CH2Cl2 (1.5ml), MeOH (0.3ml, 7.40mmol)
was added and the reaction mixture was stirred 3.5 h at r.t., under
nitrogen atmosphere. After the filtration of DCU, the solvent was
evaporated and the residue was taken up with CH2Cl2. The organic
solution was washed successively with cold 0.5 N HCl, cold 5%
(w/w) NaHCO3 and finally with iced water and brine and then it
was dried with anhydrous Na2SO4, filtered and evaporated to dry-
ness to yield the pure ester 44 as a pale yellow oil. Yield: 89%. 1H-
NMR (300MHz, CDCl3): d¼ 3.67 (s, 3H, OCH3), 3.32 (s, 3H, CH3),
3.18 (t, 2H, J¼ 7.2 Hz, CH2COO), 2.37 (t, 2H, J¼ 7.2 Hz, SCH2), 1.83-
1.76 (m, 4H, CH2) ppm.
13C-NMR (75MHz, CDCl3): d¼ 173.3, 51.6,
50.6, 35.9, 33.1, 28.8, 23.6 ppm. HRMS (ESI) m/z Calcd for
C7H15O4S2 [MþH]þ: 227.04118; found: 227.04058.
5-(Methylsulfonyl)pentanoic acid (8)
To a solution of sodium methanesulfinate (2 g, 19.03mmol) in
anhydrous N,N-dimethylformamide (12ml), 5-bromovaleric acid
(1.73 g, 9.51mmol) was added. The mixture was stirred at 60 C for
5 h. The solution was evaporated under reduced pressure and the
obtained residue was taken up with iced-water and acidified with
a cold solution of 2M KHSO4. The aqueous phase was extracted
with ethyl acetate (four times) and the combined organic extracts
were washed firstly with a cold solution of 2M KHSO4, then with
iced-water and brine. Then, the organic phase was dried with
anhydrous Na2SO4, filtered and evaporated to dryness to obtain a
yellow pale oil which crystallised spontaneously in the fridge. The
solid was rinsed with a solution of diethyl ether/petroleum ether
(1:1) to give white crystals. Yield: 27%; melting point
111.3–112.8 C. 1H-NMR (300MHz, DMSO-d6): d 12.01 (s, 1H, COOH
collapsed with D2O), 3.13 (t, 2H, J¼ 7.4 Hz, CH2), 2.92 (s, 3H, CH3),
2.23 (t, 2H, J¼ 7.4 Hz, CH2), 1.72–1.53 (m, 4H, CH2) ppm. 13C-NMR
(75MHz, CD3OD): d¼ 175.4, 53.4, 39.2, 32.7, 23.3, 21.5 ppm. HRMS
(ESI) m/z Calcd for C6H13O4S [MþH]þ: 181.05345; found:
181.05287.
Methyl 3-(allyldisulfanyl)propanoate (10)
Methanol (0.45ml, 10.43mmol) was added to a stirring solution of
3-(allyldisulfanyl)propaonic acid (ACS81, 300mg, 1.68mmol), DCC
(379.1mg, 1.84mmol) and DMAP (17.9mg, 0.16mmol) in anhyd-
rous dichloromethane (1.5ml) under inert atmosphere. The reac-
tion was monitored by thin layer chromatography (eluent phase
cyclohexane:ethylacetate/1:1) and was completed within 2 h, stir-
ring at room temperature. After the filtration of DCU, the solvent
was evaporated and the residue was taken up with dichlorome-
thane and washed firstly with a cold solution of 0.5 N HCl, then
with a cold solution of 5% NaHCO3, finally with iced water and
brine. The organic layer was dried with anhydrous Na2SO4, filtered
and evaporated to dryness to obtain the final product as a yellow
pale oil. Yield: 80%. 1H-NMR (300MHz, CDCl3): d 5.91–5.77 (m, 1H,
CH¼CH2), 5.24–5.13 (m, 2H, CH¼CH2), 3.70 (s, 3H, CH3), 3.33 (d,
2H, J¼ 7.5 Hz, CH2), 2.93 (t, 2H, J¼ 7.2 Hz, CH2), 2.74 (t, 2H,
J¼ 7.2 Hz, CH2) ppm. 13C-NMR (75MHz, CD3OD): d¼ 172.5, 133.4,
117.3, 47.1, 41.5, 33.4, 33.3 ppm.
Ferulic acid derivatives
(E)-(2-methoxyethoxy)methyl 3-(3-methoxy-4-((2-methoxyethoxy)-
methoxy)phenyl)acrylate (34)
To a solution of ferulic acid (100mg, 0.52mmol) and DIPEA
(0.27ml, 1.03mmol) in anhydrous CHCl3 (2ml) at 0 C, 2-methoxye-
thoxymethyl chloride (0.18ml, 1.55mmol) dissolved in anhydrous
CHCl3 (1ml) was added dropwise for 5min (Scheme 2). After
5min, the ice-bath was removed and the mixture was stirred at r.t.
for 5 h under inert atmosphere. After 3 h, 2-methoxyethoxymethyl
chloride (0.03ml, 0.22mmol) was added in order to speed up the
reaction and it was monitored by TLC. After the completion of
reaction, the solution was washed with 0.5 N HCl and then with
5% NaHCO3. The organic layer was dried with anhydrous Na2SO4,
filtered and evaporated to dryness to obtain a yellow pale oil.
Yield: 99%. 1H-NMR (300MHz, DMSO-d6): d¼ 7.64 (d, 1H,
J¼ 15.9 Hz, CH¼CH), 7.41 (d, 1H, J¼ 1.6 Hz, ArH), 7.23 (d, 1H,
J¼ 8.2 Hz, ArH), 7.09 (dd, 1H, J¼ 1.6 and 8.2 Hz, ArH), 6.60 (d, 1H,
J¼ 15.9 Hz, CH¼CH), 5.36 (s, 2H, OCH2O), 5.26 (s, 2H, OCH2O),
3.81 (s, 3H, OCH3), 3.74–3.70 (m, 4H, CH2), 3.48–3.43 (m, 4H, CH2),
3.23 (s, 3H, OCH3), 3.20 (s, 3H, OCH3) ppm.
13C-NMR (75MHz,
DMSO-d6): d¼ 166.3, 150.2. 148.7, 145.7, 128.6, 122.9, 116.3, 111.7,
109.9, 93.9, 89.1, 71.4, 71.3, 69.2, 68.0, 58.5, 58.4, 56.1 ppm. HRMS
(ESI) m/z Calcd for C18H27O8 [MþH]þ: 371.17059; found:
371.17029.
(E)-3-(3-methoxy-4-((2-methoxyethoxy)methoxy)phenyl)acrylic acid
(35)
(E)-(2-Methoxyethoxy)methyl 3-(3-methoxy-4-((2-methoxyethoxy)
methoxy) phenyl) acrylate (34, 1420mg, 3.83mmol) and lithium
hydroxide monohydrate (1450mg, 34.47mmol) dissolved in 15ml
of THF/H2O solution (2:1), were stirred for 24 h at r.t. The reaction
was monitored by TLC. After the completion of reaction, the THF
was evaporated under reduced pressure. The obtained residue
was acidified with a solution of 0.5 N HCl and the aqueous phase
was extracted three times with EtOAc. The organic layer was
washed with brine and dried with anhydrous Na2SO4, filtered and
evaporated to dryness to obtain a pale pink oil which was crystal-
lised with ethyl ether providing the title compound as a white
solid; melting point 78.4–79.8 C. Yield: 84%. 1H-NMR (300MHz,
DMSO-d6): d¼ 12.24 (s, 1H, COOH collapsed with D2O), 7.51 (d, 1H,
J¼ 15.9 Hz, CH¼CH), 7.34 (d, 1H, J¼ 1.6 Hz, ArH), 7.17 (d, 1H,
J¼ 8.2 Hz, ArH), 7.08 (dd, 1H, J¼ 1.6 and 8.2 Hz, ArH), 6.46 (d, 1H,
J¼ 15.9 Hz, CH¼CH), 5.25 (s, 2H, OCH2O), 3.80 (s, 3H, OCH3),
3.74–3.70 (m, 2H, CH2), 3.48–3.43 (m, 2H, CH2), 3.20 (s, 3H, OCH3)
ppm. 13C-NMR (75MHz, CDCl3): d¼ 172.4, 149.7, 148.8, 146.7,
128.3, 122.7, 115.7, 115.5, 110.4, 94.1, 71.4, 67.9, 58.9, 55.8 ppm.
HRMS (ESI) m/z Calcd for C14H19O6 [MþH]þ: 383.11816; found:
283.11790.
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3-(3-Methoxy-4-((2-methoxyethoxy)methoxy)phenyl)acrylate esters
(36, 37, 39, 40) (general method)
To a solution of (E)-3-(3-methoxy-4-((2-methoxyethoxy)methoxy)-
phenyl)acrylic acid (109mg, 0.53mmol) and the appropriate ROH
(1, 2, 3, 5; 1 or 1.1 eq) in anhydrous CH2Cl2 (2–5ml) or anh. THF
(5ml), DCC (109mg, 0.53mmol) and DMAP (7mg, 0.05mmol) were
added. The reaction mixture was stirred for 5 h at r.t. under inert
atmosphere. After the filtration of DCU, the residue was diluted
with CH2Cl2 and washed three times with a cold solution of 0.5 N
HCl and then with iced-water and finally with brine. The organic
layer was dried with anhydrous Na2SO4, filtered and the solvent
was removed under reduced pressure. The resulting residue was
purified by CC (silica gel; CH2Cl2/MeOH; in gradient as indicated
for each compound).
(E)-2-(methylsulfonylthio)ethyl 3-(3-methoxy-4-((2-methoxyethoxy)-
methoxy)phenyl)acrylate (36)
CC (silica gel; CH2Cl2/MeOH; in gradient up to 99:1). The title com-
pound was obtained as a pale yellow oil. Yield: 77%. 1H-NMR
(300MHz, CDCl3): d¼ 7.67 (d, 1H, J¼ 15.9 Hz, CH¼CH), 7.22 (dd,
1H, J¼ 1.9 and 8.2 Hz, ArH), 7.10 (d, 1H, J¼ 8.2 Hz, ArH), 7.06 (d,
1H, J¼ 1.9 Hz, ArH), 6.32 (d, 1H, J¼ 15.9 Hz, CH¼CH), 5.37 (s, 2H,
OCH2O), 4.52 (t, 2H, J¼ 6.6 Hz, COOCH2), 3.92 (s, 3H, OCH3), 3.83 (t,
2H, J¼ 3.8, CH2), 3.55 (t, 2H, J¼ 3.8, CH2), 3.50 (t, 2H, J¼ 6.6 Hz,
CH2S), 3.40 (s, 3H, CH3), 3.37 (s, 3H, OCH3) ppm. 13C-NMR (75MHz,
CDCl3): d¼ 167.9, 150.9, 145.5, 140.1, 129.2, 121.0, 116.24, 110.8,
109.9, 95.0, 71.3, 67.7, 62.4, 55.1, 53.3, 39.0, 35.2 ppm.
(E)-4-(methylsulfonylthio)butyl 3-(3-methoxy-4-((2-methoxyethoxy)-
methoxy)phenyl)acrylate (37)
CC (silica gel; CH2Cl2/MeOH; in gradient up to 99.6:0.4). Yellow oil.
Yield: 70%. 1H-NMR (300MHz, DMSO-d6): d¼ 7.61 (d, 1H,
J¼ 15.6 Hz, CH¼CH), 7.39 (d, 1H, J¼ 1.5 Hz, ArH), 7.21 (dd, 1H,
J¼ 1.5 and 8.1 Hz, ArH), 7.09 (d, 1H, J¼ 8.1 Hz, ArH), 6.59 (d, 1H,
J¼ 15.6 Hz, CH¼CH), 5.25 (s, 2H, OCH2O), 4.19–4.15 (m, 2H,
COOCH2), 3.79 (s, 3H, OCH3), 3.73–3.68 (m, 2H, CH2), 3.51 (s, 3H,
CH3), 3.48–3.42 (m, 2H, CH2), 3.30–3.22 (m, 3H, CH2S), 3.21 (s, 2H,
OCH3), 1.80–1.72 (m, 4H, CH2) ppm. 13C-NMR (75MHz, CDCl3):
d¼ 167.0, 149.7, 148.6, 144.8, 128.6, 122.3, 115.9, 115.8, 110.3, 94.1,
71.5, 67.9, 63.4, 59.0, 55.9, 50.7, 35.9, 27.6, 26.3 ppm.
(E)-2-(allyldisulfanyl)ethyl 3-(3-methoxy-4-((2-methoxyethoxy)me-
thoxy)phenyl)acrylate (39)
CC (silica gel; CH2Cl2/MeOH; in gradient up to 99.9:0.1). The title
compound was obtained as an old-rose oil. Yield: 80%. 1H-NMR
(300MHz, CDCl3): d¼ 7.68 (d, 1H, J¼ 15.9 Hz, CH¼CH), 7.31 (d, 1H,
J¼ 1.3 Hz, ArH), 7.22 (d, 1H, J¼ 8.2 Hz, ArH), 7.12 (dd, 1H, J¼ 1.3
and 8.2 Hz, ArH), 6.38 (d, 1H, J¼ 15.9 Hz, CH¼CH), 5.96-5.90 (m,
1H, CH¼CH2), 5.41 (s, 2H, OCH2O), 5.29–5.17 (m, 2H, CH¼CH2),
4.51–4.43 (m, 2H, CH2), 3.93 (s, 3H, OCH3), 3.88–3.84 (m, 2H, CH2),
3.59–3.56 (m, 2H, CH2), 3.39 (s, 3H, OCH3), 3.38–3.35 (m, 2H, CH2),
3.09–2.97 (m, 2H, CH2) ppm. 13C-NMR (75MHz, CDCl3): d¼ 166.8,
149.7, 148.6, 145.1, 133.2, 128.6, 122.4, 118.7, 115.8, 115.7, 110.2,
94.1, 71.4, 67.9, 62.4, 58.9, 55.8, 42.3, 37.3 ppm.
(E)-4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 3-(3-methoxy-4-((2-
methoxyethoxy)methoxy)phenyl) acrylate (40)
The solid residue was crystallised with a solution of CH2Cl2/MeOH
(3:0.5) to give the title compound as an orange solid. Yield: 68%;
melting point 105.7–108.2 C. 1H-NMR (300MHz, DMSO-d6):
d¼ 7.99 (d, 2H, J¼ 7.9 Hz, ArH), 7.84 (s, 1H, CH¼C), 7.82 (d, 1H,
J¼ 15.9 Hz, CH¼CH), 7.50 (d, 1H, J¼ 1.6 Hz, ArH), 7.40 (d, 2H,
J¼ 7.9 Hz, ArH), 7.33 (d, 1H, J¼ 8.2 Hz, ArH), 7.13 (dd, 1H, J¼ 1.6
and 8.2 Hz, ArH), 6.84 (d, 1H, J¼ 15.9 Hz, CH¼CH), 5.29 (s, 2H,
OCH2O), 3.83 (s, 3H, OCH3), 3.73 (t, 2H, J¼ 5.8 Hz, CH2), 3.45 (t, 2H,
Scheme 2. Reagents and conditions: (a) MEM-Cl, DIPEA, anh. CH2Cl2, 5 h, 0 C to r.t.; (b) LiOHH2O, THF/H2O (2:1), 24 h, r.t.; (c) RH (1–5), DCC (EDAC for 38), DMAP,
anh. CH2Cl2 (CHCl3 for 38), 3–20 h, r.t.; (d) TFA, anh. CH2Cl2, 4–7 h, r.t.
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J¼ 5.8 Hz, CH2), 3.21 (s, 3H, OCH3) ppm. 13C-NMR (75MHz, DMSO-
d6): d¼ 216.1, 173.4, 165.5, 154.2, 150.6, 148.7, 146.6, 136.4, 135.6,
126.1, 124.5, 123.6, 116.3, 113.2, 111.9, 94.5, 71.4, 68.1, 66.4,
58.5 ppm.
(E)-S-2-(3-(3-methoxy-4-((2-methoxyethoxy)methoxy)phenyl)acryla-
mido)ethyl methanesulfonothioate (38)
S-2-aminoethyl methanesulfonothioate hydrobromide (3, 230mg,
0.97mmol) and DIPEA (0.17ml, 0.97mmol) were mixed together in
anhydrous CHCl3 (8ml) and (E)-3-(3-methoxy-4-((2-methoxyethoxy)-
methoxy) phenyl)acrylic acid (250mg, 0.89mmol), EDAC (254mg,
1.34mmol) and DMAP (11mg, 0.09mmol) were added at r.t. The
reaction mixture was stirred for 4 h under inert atmosphere and it
was monitored by TLC. The obtained residue was poured into a
separation funnel, firstly washed with a cold solution of 0.5 N HCl,
then with cold water and finally with brine. The organic layer was
dried with anhydrous Na2SO4, filtered and the solvent was
stripped off to obtain the title compound as a yellow pale oil.
Yield: 96%. 1H-NMR (300MHz, DMSO-d6): d¼ 8.85 (s, 1H, NH col-
lapsed with D2O), 7.38 (d, 1H, J¼ 15.6 Hz, CH¼CH), 7.19 (d, 1H,
J¼ 1.8 Hz, ArH), 7.11 (dd, 1H, J¼ 1.8 and 8.5 Hz, ArH), 7.09 (d, 1H,
J¼ 8.5 Hz, ArH), 6.51 (d, 1H, J¼ 15.6 Hz, CH¼CH), 5.23 (s, 2H,
OCH2O), 3.79 (s, 3H, OCH3), 3.73–3.70 (m, 2H, NHCH2), 3.54 (s, 3H,
CH3), 3.51 (t, 2H, J¼ 6Hz, CH2), 3.46–3.43 (m, 2H, CH2S), 3.31 (t,
2H, J¼ 6Hz, CH2), 3.20 (s, 3H, OCH3) ppm. 13C-NMR (75MHz,
CD3OD): d¼ 167.7, 150.2, 148.0, 140.7, 129.4, 121.2, 118.4, 116.5,
110.7, 94.0, 71.4, 67.6, 57.6, 55.0, 49.3, 38.8, 35.2 ppm.
3-(4-Hydroxy-3-methoxyphenyl)acrylate esters (14, 15, 17, 18) and
amide (16) (general method)
To a solution of the appropriate 3-(3-methoxy-4-((2-methoxyethox-
y)methoxy)phenyl)acrylate derivative (32–36) (0.38mmol) in
anhydrous CH2Cl2 (2ml), trifluoroacetic acid (0.16ml, 2.12mmol)
was added and the mixture was stirred at r.t. for 5-7 h. The reac-
tion was monitored by TLC and after its completion, the solvent
and the trifluoroacetic acid were evaporated in vacuo. The
obtained residue was diluted with CH2Cl2, washed twice with a
cold solution of NaHCO3 at 5% (w/w) and then with iced-brine.
The organic layer was dried with anhydrous Na2SO4, filtered and
evaporated to dryness to obtain a residue that was purified by CC
(silica gel; eluent as indicated for each compound).
(E)-2-(methylsulfonylthio)ethyl 3-(4-hydroxy-3-methoxyphenyl)acry-
late (14)
CC (CH2Cl2; isocratic): a colorless oil was obtained. Yield: 64%.
1H-
NMR (300MHz, DMSO-d6): d¼ 9.64 (br s, 1H, OH collapsed with
D2O), 7.58 (d, 1H, J¼ 15.9 Hz, CH¼CH), 7.32 (d, 1H, J¼ 1.9 Hz,
ArH), 7.12 (dd, 1H, J¼ 1.9 and 8.2 Hz, ArH), 6.78 (d, 1H, J¼ 8.2 Hz,
ArH), 6.48 (d, 1H, J¼ 15.9 Hz, CH¼CH), 4.41 (t, 2H, J¼ 6.1 Hz,
COOCH2), 3.80 (s, 3H, OCH3), 3.58 (s, 3H, CH3), 3.53 (t, 2H,
J¼ 6.1 Hz, CH2S) ppm. 13C-NMR (75MHz, CDCl3): d¼ 166.7, 148.3,
146.8, 146.1, 126.6, 123.2, 144.8, 114.2, 109.5, 62.2, 55.9, 50.9,
35.1 ppm. HRMS (ESI) m/z Calcd for C13H17O6S2 [MþH]þ:
333.04665; found: 333.04606.
(E)-4-(methylsulfonylthio)butyl 3-(4-hydroxy-3-methoxyphenyl)acry-
late (15)
CC (CH2Cl2/MeOH; in gradient up to 99.5:0.5). Light-gray oil. Yield:
64%. 1H-NMR (300MHz, DMSO-d6): d¼ 9.60 (br s, 1H, OH collapsed
with D2O), 7.53 (d, 1H, J¼ 15.7 Hz, CH¼CH), 7.30 (d, 1H, J¼ 1.4 Hz,
ArH), 7.10 (dd, 1H, J1¼1.4 and 8.6 Hz, ArH), 6.78 (d, 1H, J¼ 8.6 Hz,
ArH), 6.45 (d, 1H, J¼ 15.7 Hz, CH¼CH), 4.14 (t, 2H, J¼ 6.15Hz,
COOCH2), 3.79 (s, 3H, OCH3), 3.51 (s, 3H, CH3), 3.30–3.22 (m, 3H,
CH2S), 1.80–1.72 (m, 4H, CH2) ppm. 13C-NMR (75MHz, CDCl3):
d¼ 167.1, 148.0, 146.8, 145.1, 126.8, 123.1, 115.1, 114.7, 109.4, 63.3,
55.9, 50.7, 35.9, 27.6, 26.3 ppm. HRMS (ESI) m/z Calcd for
C15H21O6S2 [MþH]þ: 361.07795; found: 361.07734.
(E)-S-2-(3-(4-hydroxy-3-methoxyphenyl)acrylamido)ethyl methane-
sulfonothioate (16)
CC (CH2Cl2/MeOH; in gradient up to 99.5:0.5). Light-gray oil. Yield:
50%. 1H-NMR (300MHz, DMSO-d6): d¼ 9.46 (s, 1H, OH collapsed
with D2O), 9.29 (s, 1H, NH collapsed with D2O), 7.34 (d, 1H,
J¼ 15.6 Hz, CH¼CH), 7.12 (d, 1H, J¼ 1.8 Hz, ArH), 6.99 (dd, 1H,
J¼ 1.8 and 7.9 Hz, ArH), 6.78 (d, 1H, J¼ 7.9 Hz, ArH), 6.42 (d, 1H,
J¼ 15.6 Hz, CH¼CH), 3.79 (s, 3H, OCH3), 3.56–3.50 (m, 2H, NHCH2),
3.54 (s, 3H, CH3), 3.32–3.30 (m, 2H, CH2S) ppm. 13C-NMR (75MHz,
DMSO-d6): d¼ 166.4, 149.1, 148.5, 140.2, 126.9, 122.3, 119.0, 116.3,
111.5, 56.2, 50.9, 39.0, 36.1. HRMS (ESI) m/z Calcd for C13H18NO5S2
[MþH]þ: 332.06264; found: 332.06205.
(E)-2-(allyldisulfanyl)ethyl 3-(4-hydroxy-3-methoxyphenyl)acrylate
(17)
CC (CH2Cl2/MeOH; in gradient 99.9:0.1). Colorless oil. Yield: 35%.
1H-NMR (300MHz, DMSO-d6): d¼ 9.62 (br s, 1H, OH collapsed with
D2O), 7.59 (d, 1H, J¼ 15.9 Hz, CH¼CH), 7.37 (d, 1H, J¼ 1.1 Hz,
ArH), 7.11 (d, 1H, J¼ 8.2 Hz, ArH), 7.81 (dd, 1H, J¼ 1.1 and 8.2 Hz,
ArH), 6.49 (d, 1H, J¼ 15.9 Hz, CH¼CH), 5.91–5.73 (m, 1H,
CH¼CH2), 5.29–5.08 (m, 2H, CH¼CH2), 4.48–4.31 (m, 2H,
COOCH2), 3.82 (s, 3H, OCH3), 3.42–3.38 (m, 2H, CH2S), 3.07–2.96
(m, 2H, SCH2) ppm. 13C-NMR (75MHz, CDCl3): d¼ 166.9, 148.1,
146.7, 145.4, 133.2, 126.8, 123.2, 118.7, 114.9, 114.7, 109.3, 62.1,
55.9, 42.3, 37.3 ppm. HRMS (ESI) m/z Calcd for C15H17O4S2 [M–H]
–:
325.05683; found: 325.0549.
(E)-4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 3-(4-hydroxy-3-methoxy-
phenyl)acrylate (18)
After the completion of reaction, the solution was filtered and the
resulting solid residue was rinsed with a solution of ethyl ether/
CH2Cl2 (4:1) for two times to provide orange crystals. Yield: 72%.
Melting point 204.5–206.8 C. 1H-NMR (300MHz, DMSO-d6):
d¼ 9.75 (br s, 1H, OH collapsed with D2O), 7.99 (d, 2H, J¼ 8.7 Hz,
ArH), 7.80 (d, 1H, J¼ 15.9 Hz, CH¼CH), 7.44 (s, 1H, ArH), 7.39 (m,
3H, ArH), 7.22 (dd, 1H, J¼ 1.6 and 8.2 Hz, ArH), 6.28 (d, 1H,
J¼ 8.2 Hz, ArH), 6.74 (d, 1H, J¼ 15.9 Hz, CH¼CH), 3.83 (s, 3H,
OCH3) ppm. 13C-NMR (75MHz, DMSO-d6): d¼ 216.1, 173.4, 165.5,
154.3, 150.7, 148.7, 148.4, 136.4, 129.3, 126.0, 124.5, 123.8, 116.2,
113.5, 112.2, 56.4. HRMS (ESI) m/z Calcd for C19H15O4S3 [MþH]þ:
403.01325; found: 403.01282.
Caffeic acid derivatives
(E)-methyl 3-(3,4-bis((2-methoxyethoxy)methoxy)phenyl)acrylate
(41)
To a solution of 60% sodium hydride (w/w) in mineral oil (375mg,
9.37mmol) dissolved in anhydrous THF (12ml) at 0 C under nitro-
gen, (E)-methyl 3-(3,4-dihydroxyphenyl)acrylate (20, 500mg,
2.58mmol) diluted in anhydrous THF (6ml) was added dropwise
(Scheme 3). After 10min, 2-methoxyethoxymethyl chloride (1.30 g,
10.32mmol) in anhydrous THF (5ml) was added slowly and the
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mixture was stirred at 0 C for 5 h under inert atmosphere. After
its completion, a saturated solution of NH4Cl was added and the
aqueous phase was extracted three times with CH2Cl2. The organic
layer was dried with anhydrous Na2SO4, filtered and the solvent
was evaporated under reduced pressure to provide a residue that
was purified by CC (silica gel; EtOAc/cyclohexane in ratio 7:3; iso-
cratic). The fractions containing the purified product were gath-
ered up and the title compound was obtained as a yellow
oil. Yield: 75%. 1H-NMR (300MHz, DMSO-d6): d¼ 7.56 (d,
1H, J¼ 15.9 Hz, CH¼CH), 7.48 (d, 1H, J¼ 1.2 Hz, ArH), 7.31
(d, 1H, J¼ 8.2 Hz, ArH), 7.12 (dd, 1H, J¼ 1.2 and 8.2 Hz, ArH), 6.49
(d, 1H, J¼ 15.9 Hz, CH¼CH), 5.27 (s, 4H, OCH2O), 3.85–3.62 (m, 7H,
CH3 and CH2), 3.52–3.37 (m, 4H, CH2), 3.20 (s, 6H, CH3) ppm. 13C-
NMR (75MHz, CDCl3): d¼ 167.5, 149.1, 147.2, 144.4, 128.8, 123.5,
116.3, 116.1, 115.9, 94.5, 94.1, 71.4, 71.3, 67.9, 67.8, 59.0, 58.9,
51.6 ppm. HRMS (ESI) m/z Calcd for C18H26O8Na [MþNa]þ:
393.15254; found: 393.15189.
(E)-3-(3,4-bis((2-methoxyethoxy)methoxy)phenyl)acrylic acid (42)
(E)-methyl 3-(3,4-bis((2-methoxyethoxy)methoxy)phenyl)acrylate
(1.33 g, 3.59mmol) dissolved in a mixture of THF/MeOH in ratio
4:1 (16ml), was treated with a solution of 5 N NaOH (4.3ml). The
resulting mixture was stirred at 40 C for 3 h. After the completion
of reaction, THF and MeOH were evaporated to dryness and the
basic aqueous phase was washed with EtOAc in order to remove
the unreacted ester. The aqueous mixture was acidified with a
solution of 6N HCl and was extracted three times with EtOAc. The
organic layer was dried with anhydrous Na2SO4, filtered and
evaporated in vacuo to obtain a yellow oil, which was crystallised
with diethyl ether: (E)-3-(3,4-bis((2-methoxyethoxy)methoxy)pheny-
l)acrylic acid was obtained as white solid. Melting point
56.6–58.3 C. Yield: 98%. 1H-NMR (300MHz, DMSO-d6): d¼ 12.08 (s,
1H, COOH collapsed with D2O), 7.48 (d, 1H, J¼ 15.9 Hz, CH¼CH),
7.44 (d, 1H, J¼ 1.5 Hz, ArH), 7.27 (dd, 1H, J¼ 1.5 and 8.2 Hz, ArH),
7.12 (d, 1H, J¼ 8.2 Hz, ArH), 6.38 (d, 1H, J¼ 15.9 Hz, CH¼CH), 5.26
(s, 4H, OCH2O), 3.80–3.65 (m, 4H, CH2), 3.55–3.38 (m, 4H, CH2), 3.21
(s, 6H, CH3) ppm. 13C-NMR (75MHz, CDCl3): d¼ 171.9, 149.4, 147.2,
146.2, 128.5, 123.9, 116.1, 116.0, 115.9, 94.4, 93.9, 71.4, 71.3, 67.9,
67.8, 59.0, 58.9 ppm. HRMS (ESI) m/z Calcd for C17H25O8 [MþH]þ:
357.15494; found: 357.15489.
3-(3,4-bis((2-Methoxyethoxy)methoxy)phenyl)acrylate esters (28,
43, 44) (general method)
(E)-3-(3,4-bis((2-methoxyethoxy)methoxy)phenyl)acrylic acid (355mg,
1mmol) and the appropriate ROH (1, 3, 5; 1mmol) were mixed
together in anhydrous CH2Cl2 or THF (4ml), and DCC (206mg,
1mmol) and a catalytic amount of DMAP were added at r.t. The
reaction mixture was stirred for 5–20h under inert atmosphere and
it was monitored by TLC. After the filtration of DCU, the solvent
was evaporated under reduced pressure and the residue was dis-
solved in ethyl acetate and washed three times first with a cold
solution of 0.5N HCl, then with a cold solution of 5% (w/w)
NaHCO3 and finally with cold brine. The organic layer was dried
with anhydrous Na2SO4, filtered and the solvent was removed
under reduced pressure. The resulting residue was purified by CC
(silica gel; CH2Cl2/MeOH or EtOAc/cyclohexane in gradient as indi-
cated for each compound).
(E)-2-(methylsulfonylthio)ethyl 3-(3,4-bis((2-methoxyethoxy)methox-
y)phenyl)acrylate (28)
CC (CH2Cl2/MeOH; in gradient up to 98.4:1.6). Yellow oil. Yield:
53%. 1HNMR (300MHz, DMSO-d6): d¼ 7.59 (d, 1H, J¼ 15.9 Hz,
CH¼CH), 7.50 (d, 1H, J¼ 1.2 Hz, ArH), 7.32 (dd, 1H, J¼ 1.2 and
8.2 Hz, ArH), 7.13 (d, 1H, J¼ 8.2 Hz, ArH), 6.50 (d, 1H, J¼ 15.9 Hz,
CH¼CH), 5.27 (s, 4H, OCH2O), 4.42 (t, 2H, J¼ 6Hz, CH2), 3.80–3.65
(m, 4H, CH2), 3.57 (s, 3H, CH3), 3.53 (t, 2H, J¼ 6Hz, CH2), 3.50-3.38
(m, 4H, CH2), 3.21 (s, 6H, CH3) ppm. 13C-NMR (75MHz, CDCl3):
d¼ 166.6, 149.4, 147.3, 145.6, 128.5, 123.7, 116.1, 115.8, 115.4, 94.5,
94.1, 77.2, 71.5, 68.0, 67.9, 62.3, 59.1, 50.9, 50.9, 35.2 ppm. HRMS
(ESI) m/z Calcd for C18H26O10S2Na [MþNa]þ: 517.11781; found:
517.11682.
Scheme 3. Reagents and conditions: (a) H2SO4 (cat.), MeOH, reflux, 2 h; (b) NaH, MEM-Cl, anh. THF, 0 C, 5 h; (c) 5 N NaOH, THF/MeOH (4:1), 40 C, 3 h; (d) RH (1, 3–5),
DCC or EDAC (for 29), DMAP, anh. THF or CH2Cl2 or CHCl3, 4–20 h, r.t.; (e) TFA, anh. CH2Cl2 or CHCl3, 5–8 h, r.t.
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(E)-2-(allyldisulfanyl)ethyl 3-(3,4-bis((2-methoxyethoxy)methoxy)-
phenyl)acrylate (43) and N-acylurea by-product (45)
(a) The raw yellow oil initially obtained was partially crystallised in
freezer; after dilution with ether and filtration, white crystals have
been obtained, which resulted to be the N-acylurea (45). (b) The
ethereal mothers, evaporated to dryness were purified through CC
(CH2Cl2/MeOH; in gradient up to 99:1) to achieve compound (43).
(E)-3-(3,4-bis((2-methoxyethoxy)methoxy)phenyl)-N-cyclohexyl-N-
(cyclohexylcarbamoyl) acrylamide (45)
1H-NMR (300MHz, CDCl3): d¼ 7.58 (d, 1H, J¼ 15.6 Hz, CH¼CH),
7.34 (d, 1H, J¼ 1.4 Hz, ArH), 7.21 (d, 1H, J¼ 8.2 Hz), 7.10 (dd, 1H,
J¼ 1.4 and 8.2 Hz, ArH), 7.05 (br s, 1H, NH collapsed with D2O),
6.61 (d, 1H, J¼ 15.6 Hz, CH¼CH), 5.33 (s, 2H, CH2), 5.30 (s, 2H,
CH2) 4.10–4.09 (m, 1H, CH), 3.87–3.83 (m, 4H, CH2), 3.75–3.73 (m,
1H, CH), 3.57–3.36 (s, 6H, OCH3), 1.99–1.58 (m, 10H, CH), 1.41–1.14
(m, 10H, CH) ppm. 13C-NMR (75MHz, CDCl3): d¼ 167.1, 154.1,
149.0, 147.3, 143.1, 129.2, 122.9, 118.06, 116.3, 116.2, 94.6, 94.1,
77.0, 71.5, 71.4, 67.9, 59.0, 56.2, 49.8, 32.8, 30.9, 26.2, 26.2, 25.4,
25.3, 24.66 ppm. HRMS (ESI) m/z Calcd for C30H47N2O8 [MþH]þ:
563.33324; found: 563.33222.
(E)-2-(Allyldisulfanyl)ethyl 3-(3,4-bis((2-methoxyethoxy)methoxy)-
phenyl)acrylate (43)
Yellow oil. Yield: 40%. 1H-NMR (300MHz, DMSO-d6): d¼ 7.56 (d,
1H, J¼ 15.6 Hz, CH¼CH), 7.48 (d, 1H, J¼ 1.2 Hz, ArH), 7.30 (dd, 1H,
J¼ 1.2 mand 8.2 Hz, ArH), 7.11 (d, 1H, J¼ 8.2 Hz, ArH), 6.49 (d, 1H,
J¼ 15.6 Hz, CH¼CH), 5.90–5.70 (m, 1H, CH¼CH2), 5.40–5.00 (m,
6H, OCH2O and CH¼CH2), 4.35 (d, 2H, J¼ 6.3 Hz, CH2), 3.85–3.60
(m, 4H, CH2), 3.52–3.35 (m, 6H, CH2), 3.20 (s, 6H, OCH3), 3.01 (d,
2H, J¼ 6.3 Hz, CH2) ppm. 13C-NMR (75MHz, CDCl3): d¼ 166.8,
149.2, 147.2, 144.8, 133.2, 128.7, 123.6, 118.8, 116.1, 115.9, 109.9,
94.5, 94.0, 71.4, 71.3, 68.0, 67.9, 62.4, 59.1, 59.0, 42.3, 37.2 ppm.
(E)-4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 3-(3,4-bis((2-methoxye-
thoxy)methoxy)phenyl) acrylate (44)
CC (EtOAc/cyclohexane; in gradient up to 37:63). A red oil was
obtained which crystallized spontaneously in the fridge during the
night. The solid was rinsed with petroleum ether to give orange
crystals. Yield: 60%. Melting point 81.4–84.0 C. 1H-NMR (300MHz,
DMSO-d6): d¼ 7.98 (d, 2H, J¼ 8.8 Hz, ArH), 7.84–7.76 (m, 2H,
CH¼CH and ArH), 7.59 (d, 1H, J¼ 1.2 Hz, ArH), 7.47–7.32 (m, 3H,
ArH), 7.17 (d, 1H, J¼ 8.8, ArH), 6.76 (d, 1H, J¼ 15.9 Hz, CH¼CH),
5.30 (s, 4H, OCH2O), 3.78–3.70 (m, 4H, CH2), 3.50–3.41 (m, 4H, CH2),
3.21 (s, 6H, OCH3) ppm.
13C-NMR (75MHz, DMSO-d6): d¼ 215.9,
173.2, 165.1, 154.0, 150.1, 147.3, 147.2, 136.2, 129.1, 128.2, 124.9,
123.6, 117.2, 116.7, 115.3, 94.3, 93.9, 71.4, 71.3, 68.1, 68.0, 58.5,
68.4 ppm.
(E)-S-2-(3-(3,4-bis((2-methoxyethoxy)methoxy)phenyl)acrylami-
do)ethyl methanesulfonothioate (29)
S-2-aminoethyl methanesulfonothioate hydrobromide (3, 101mg,
0.65mmol) and DIPEA (0.11ml, 0.65mmol) were mixed together in
anhydrous CHCl3 (4ml) and (E)-3-(3,4-bis((2-methoxyethoxy)me-
thoxy)phenyl)acrylic acid (212mg, 0.59mmol), EDAC (107mg,
0.89mmol) and DMAP (7.3mg, 0.06mmol) were added at r.t. The
reaction mixture was stirred for 4 h under argon and it was moni-
tored by TLC. The obtained residue was poured into a separation
funnel, firstly washed with a cold solution of 0.5 N HCl, then with
a cold solution of 5% (w/w), NaHCO3 and finally with cold brine.
The organic layer was dried with anhydrous Na2SO4, filtered and
the solvent was removed under reduced pressure to obtain a yel-
low oil, which crystallised spontaneously in the fridge during the
night. The solid was rinsed with ethyl ether to give ash gray crys-
tals. Yield: 80%. Melting point 62.3–64.6 C. 1H-NMR (300MHz,
DMSO-d6): d¼ 8.38 (s, 1H, NH collapsed with D2O), 7.38–7.30 (m,
2H, ArH and CH¼CH), 7.17 (m, 2H, ArH), 6.46 (d, 1H, J¼ 15.6 Hz,
CH¼CH), 5.26 (s, 4H, OCH2O), 3.78–3.69 (m, 4H, CH2), 3.60–3.39
(m, 9H, CH3 and CH2), 3.32 (t, 2H, J¼ 6.3 Hz, CH2S), 3.20 (s, 6H,
OCH3) ppm.
13C-NMR (75MHz, CD3OD): d¼ 167.6, 149.0, 147.4,
140.4, 129.3, 122.9, 118.6, 116.7, 116.0, 94.3, 94.0, 71.4, 71.3, 67.7,
67.6, 57.7, 57.6, 49.3, 38.7, 35.1 ppm. HRMS (ESI) m/z Calcd for
C18H28NO9S2 [MþH]þ: 494.15185; found: 494.15112.
3-(3,4-Dihydroxyphenyl)acrylate esters (21, 23, 24) and amide (22)
(general method)
To a solution of the appropriate 3-(3,4-dihydroxyphenyl)acrylate
derivative (28, 29, 43, 44; 0.42mmol) in anhydrous CH2Cl2 or
CHCl3 (2ml), trifluoroacetic acid (0.32ml, 4.21mmol) was added
and the reaction mixture was stirred, under argon, at r.t. for 5–8 h.
After the completion of reaction, the solvent and the trifluoroace-
tic acid were evaporated to dryness. The residue was washed with
the solvents indicated for each compounds or purified by CC (sil-
ica, eluent as indicated).
(E)-2-(methylsulfonylthio)ethyl 3-(3,4-dihydroxyphenyl)acrylate (21)
Solid residue washed with CH2Cl2/petroleum ether (1:1) and dried
in vacuo to afford the title compound as a white solid. Yield: 64%.
Melting point 133.1–134.8 C. 1H-NMR (300MHz, DMSO-d6):
d¼ 9.61 (br s, 1H, OH collapsed with D2O), 9.13 (br s, 1H, OH col-
lapsed with D2O), 7.50 (d, 1H, J¼ 15.9 Hz, CH¼CH), 7.04–7.00 (m,
2H, ArH), 6.47 (d, 1H, J¼ 8.9 Hz, ArH), 6.25 (d, 1H, J¼ 15.9 Hz,
CH¼CH), 4.39 (t, 2H, J¼ 6.3 Hz, CH2), 3.56 (s, 3H, CH3), 3.51 (t, 2H,
J¼ 6.3 Hz, CH2) ppm. 13C-NMR (75MHz, d6-DMSO): d¼ 166.9, 149.3,
146.5, 146.2, 126.0, 122.2, 116.4, 115.6, 113.9, 62.8, 50.8, 35.1.
HRMS (ESI) m/z Calcd for C12H15O6S2 [MþH]þ: 319.03100; found:
319.03052.
(E)-S-2-(3-(3,4-dihydroxyphenyl)acrylamido)ethyl methanesulfono-
thioate (22)
The obtained residue was purified by CC (silica gel; CH2Cl2/MeOH;
in gradient up to 99:1). The title compound was obtained as a tan
oil. Yield: 9%. 1H-NMR (300MHz, DMSO-d6): d¼ 8.25 (s, 2H, –OH
collapsed with D2O), 7.54 (s, 1H, NH collapsed with D2O), 7.42 (d,
1H, J¼ 15.6 Hz, CH¼CH), 7.08 (d, 1H, J¼ 1.1 Hz, ArH), 6.95 (dd, 1H,
J¼ 1.1 and 8.2 Hz, ArH), 6.84 (d, 1H, J¼ 8.2 Hz, ArH), 6.44 (d, 1H,
J¼ 15.6 Hz, CH¼CH), 3.78–3.60 (m, 2H, NHCH2), 3.49 (s, 3H, CH3),
3.41 (t, 2H, J¼ 6.3 Hz, CH2S) ppm. 13C-NMR (75MHz, DMSO-d6):
d¼ 166.2, 147.9, 145.9, 140.1, 126.6, 120.9, 118.2, 116.1, 114.2, 50.6,
38.8, 35.8 ppm. HRMS (ESI) m/z Calcd for C12H16NO5S2 [MþH]þ:
318.04699; found: 318.04643.
(E)-2-(allyldisulfanyl)ethyl 3-(3,4-dihydroxyphenyl)acrylate (23)
The obtained residue was taken up with CH2Cl2 and washed twice
with iced-brine. The organic layer was dried with anhydrous
Na2SO4, filtered and evaporated to dryness to obtain a residue
that was purified by preparative TLC (silica; eluent mixture:
CH2Cl2/MeOH 10:0.4). The title compound was obtained as a
green-gray oil. Yield: 42%. 1H-NMR (300MHz, acetone-d6): d¼ 8.45
(s, 1H, OH collapsed with D2O), 8.17 (s, 1H, OH collapsed with
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D2O), 7.55 (d, 1H, J¼ 15.2 Hz, CH¼CH), 7.16 (s, 1H, ArH), 7.05 (dd,
1H, J¼ 1.8 and 7.9 Hz, ArH), 6.86 (d, 1H, J¼ 7.9 Hz, ArH), 6.28 (d,
1H, J¼ 15.2 Hz, CH¼CH), 5.92–5.82 (m, 1H, CH¼CH2), 5.25–5.11
(m, 2H, CH¼CH2), 4.40 (t, 1H, J¼ 6.6 Hz, CH2), 4.28 (t, 1H,
J¼ 6.6 Hz, CH2), 3.42 (d, 1H, J¼ 7.1 Hz, CH2), 3.26 (d, 1H,
J¼ 7.1 Hz, CH2), 3.03 (t, 1H, J¼ 6.3 Hz, CH2), 2.75 (t, 1H,
J¼ 6.3 Hz, CH2) ppm. 13C-NMR (75MHz, acetone-d6): d¼ 166.3,
147.9, 145.4, 145.2, 133.5, 126.6, 121.7, 118.0, 115.5, 114.4, 124.3,
61.9, 41.6, 36.9 ppm.  The 1H NMR showed split signals for the
enantiotropic hydrogens. HRMS (ESI) m/z Calcd for C14H15O4S2
[M–H]–: 311.04118; found: 311.0395.
(E)-4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 3-(3,4-dihydroxyphenyl)a-
crylate (24)
The residue treated with crystallised CH2Cl2. The orange crystals
were filtered and washed with ethyl ether/MeOH (9:1) to provide
the title compound as an orange solid. Yield: 54%. Melting point
199.5–201.5 C. 1H-NMR (300MHz, DMSO-d6): d¼ 9.72 (br s, 1H, OH
collapsed with D2O), 9.18 (br s, 1H, OH collapsed with D2O), 7.97
(d, 2H, J¼ 8.5 Hz, ArH), 7.82 (s, 1H, ArH), 7.71 (d, 1H, J¼ 15.9 Hz,
CH¼CH), 7.37 (d, 2H, J¼ 8.5, ArH), 7.13–7.11 (m, 2H, ArH), 6.79 (d,
1H, J¼ 8.2, ArH), 6.50 (d, 1H, J¼ 15.9 Hz, CH¼CH) ppm. 13C-NMR
(75MHz, DMSO-d6): d¼ 215.8, 173.2, 165.2, 154.1, 149.5, 148.2,
146.0, 136.1, 129.0, 125.7, 123.6, 122.5, 116.2, 115.6, 112.8 ppm.
HRMS (ESI-TOF) m/z Calcd for C18H13O4S3 [MþH]þ: 388.9976;
found: 388.9972.
Various cinnamic acids derivatives
2-(Methylsulfonylthio)ethyl 3,4-substitutedcinnamate (25–27) (gen-
eral method)
To a solution of S-2-hydroxyethyl methanesulfonothioate (1,
200mg, 1.28mmol) dissolved in anhydrous CH2Cl2 or THF (5ml),
cinnamic acid or (E)-3-(3,4-dichlorophenyl)acrylic acid, or (E)-3-(3,4-
dimethoxyphenyl) acrylic acid (1.16mmol), DCC (264mg,
1.28mmol), and DMAP (12mg, 0.1mmol) were added (Scheme 4).
The reaction mixture was stirred for 1–4 h, at r.t. under inert
atmosphere and it was monitored by TLC. After the completion of
reaction, DCU was filtered and the solution was evaporated under
reduced pressure. The obtained residue was taken up with iced
EtOAc and the DCU filtered. The organic solution was washed
firstly with a cold solution of 0.5 N HCl, then with a cold solution
of 5% (w/w) NaHCO3 and finally with cold water and brine. The
organic layer was dried with anhydrous Na2SO4, filtered, and
evaporated to dryness to get a residue that was purified as indi-
cated for each compound.
2-(Methylsulfonylthio)ethyl cinnamate (25)
CC (silica gel; EtOAc/cyclohexane; 33:67). A yellow oil was
obtained, which crystallised spontaneously in the fridge during
the night. The solid was rinsed with ethyl ether to give
white-cream crystals. Yield: 62%. Melting point 76.8–78.5 C. 1H-
NMR (300MHz, DMSO-d6): d¼ 7.73 (d, 1H, J¼ 15.9 Hz, CH¼CH),
7.60–7.45 (m, 2H, ArH), 7.45–7.35 (m, 3H, ArH), 6.43 (d, 1H,
J¼ 15.9 Hz, CH¼CH), 4.52 (t, 2H, J¼ 6Hz, CH2), 3.50 (t, 2H,
J¼ 6Hz, CH2), 3.39 (s, 3H, CH3) ppm. 13C-NMR (75MHz, DMSO-d6):
d¼ 166.3, 145.7, 134.3, 131.0, 129.4, 128.9, 117.8, 62.8, 50.6,
34.8 ppm. HRMS (ESI) m/z Calcd for C12H15O4S2 [MþH]þ:
287.04118; found: 287.04078.
(E)-2-(methylsulfonylthio)ethyl 3-(3,4-dichlorophenyl)acrylate (26)
Yellow oily residue that was purified by CC (silica gel; cyclohex-
ane/EtOAc in gradient up to 65:35). The obtained residue was crys-
tallised with EtOAc and the solid was rinsed with petroleum ether
to give white crystals. Yield: 38%. Melting point 69.6–71.2 C. 1H-
NMR (300MHz, CDCl3): d¼ 7.67–7.55 (m, 2H, ArH and CH¼CH),
7.48 (d, 1H, J¼ 8.2 Hz, ArH), 7.53 (dd, 1H, J¼ 1.6 and 8.2 Hz, ArH),
6.42 (d, 1H, J¼ 15.9 Hz, CH¼CH), 4.52 (t, 2H, J¼ 6.3 Hz, CH2), 3.49
(t, 2H, J¼ 6.3 Hz, CH2), 3.39 (s, 3H, CH3) ppm. 13C-NMR (75MHz,
CDCl3): d¼ 165.7, 143.1, 134.5, 134.1, 133.3, 130.9, 129.7, 127.1,
118.8, 62.6, 50.9, 35.0 ppm. HRMS (ESI) m/z Calcd for C12H13Cl2O4S2
[MþH]þ: 354.96323; found: 354.96278.
(E)-2-((methylsulfonyl)thio)ethyl 3-(3,4-dimethoxyphenyl)acrylate
(27)
Colorless oily residue, which was crystallised from diethyl ether
into cream-white crystals. Yield: 45%. Melting point 99.8–102.7 C.
1H-NMR (300MHz, CDCl3): d¼ 7.67 (d, 1H, J¼ 15.9 Hz, CH¼CH),
7.12 (dd, 1H, J¼ 1.2 and 8.4 Hz, ArH), 7.05 (d, 1H, J¼ 1.2 Hz, ArH),
6.88 (dd, 1H, J¼ 8.4 Hz, ArH), 6.30 (d, 1H, J¼ 15.9 Hz, CH¼CH),
4.51 (t, 2H, J¼ 6.3 Hz, CH2), 3.92 (s, 6H, OCH3), 3.50 (t, 2H,
J¼ 6.3 Hz, CH2), 3.39 (s, 3H, CH3) ppm. 13C-NMR (75MHz, CDCl3):
d¼ 166.5, 151.3, 149.1, 145.8, 126.9, 122.8, 114.5, 111.0, 109.7, 62.2,
55.9, 50.8, 35.1 ppm. HRMS (ESI) m/z Calcd for C14H19O6S2
[MþH]þ: 347.06230; found: 347.06169.
Rosmaricine derivatives
Extraction of rosmaricine (30)
A total of 150 g of rosemary dry leaves were divided into three
500ml flasks and each portion was suspended in 200ml of etha-
nol and kept in an ultrasound sonicator for 1 h (from 25 to 60 C)
(Scheme 5). After cooling, the mixture was filtered on a Buchner
funnel and washed with ethanol. The residual leaves were treated
twice with the same procedure. All the filtrates were gathered and
concentrated at 100ml of solvent volume and were treated follow-
ing the procedure described by Boido et al.53 Yield (referred to
dry leaves): 0.22%. Melting point 198.2–202.5 C. 1H-NMR (DMSO-
d6) d: 8.05 (br s, 2H, collapsed with D2O); 6.77 (s, 1H); 4.37 (d, 1H,
J¼ 2.47 Hz); 3.72 (d, 1H, J¼ 2.47Hz); 3.30 (br s, 2H, collapsed with
D2O); 3.26–3.09 (m, 2H); 1.84–1.70 (m, 1H); 1.60–1.18 (m, 5H); 1.11
(d, 3H, J¼ 6.88 Hz); 1.07 (d, 3H, J¼ 6.88 Hz); 0.94 (s, 3H); 0.77 (s, 3H).
Scheme 4. Reagents and conditions: (a) DCC, DMAP, anh. CH2Cl2 or THF, r.t., 1–4 h.
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13C-NMR (75MHz, CD3OD): d¼ 179.6, 144.2, 141.5, 136.2, 134.8,
127.4, 125.8, 118.2, 117.5, 79.7, 51.8, 37.9, 30.9, 30.4, 27.6, 27.5,
26.9, 22.0, 21.8, 18.9 ppm. HRMS (ESI) m/z Calcd for C20H28NO4
[MþH]þ: 346.20183; found: 346.20127.
Amido derivatives of rosmaricine (31, 32, 33) (general method)
To a solution of the appropriate sulfurated acid (6, 9, 11;
0.29mmol) in anhydrous N,N-dimethylformamide (1ml) under
argon and at 0 C, HOBt (39.2mg, 0.29mmol), N,N-diisopropylethyl-
amine (0.05ml, 0.29mmol), and EDAC (55.6mg, 0.29mmol) were
added. After 5min, rosmaricine (100mg, 0.29mmol) was added.
The temperature was maintained at 0 C with stirring for 2.5–6 h.
After the completion of reaction, the solution was evaporated
under reduced pressure. The obtained residue was taken up with
ethyl acetate and washed firstly with a cold solution of 0.5 N HCl,
then with a cold solution of 5% NaHCO3, finally with cold brine.
The organic layer was dried with anhydrous Na2SO4, filtered and
evaporated to dryness. The crude mixture was purified as indi-
cated for each compound.
N-[5-(methylsulfonyl)thiopentanoyl]rosmaricine (31)
The green oil obtained was crystallised with a solution of diethyl
ether, EtOAc and CH2Cl2 (in ratio 1:1:1) and rinsed with diethyl
ether for several times to obtain a white solid. Yield: 38%. Melting
point 121.1–124.2 C (dec.). 1H-NMR (300MHz, DMSO-d6): d¼ 8.44
(br s, 2H, NH collapsed with D2O), 8.22 (br s, 2H, OH collapsed
with D2O), 6.46 (s, 1H, ArH), 4.83 (d, 1H, J¼ 5.1 Hz, CH), 4.33 (s,
1H), 3.47 (s, 3H), 3.23–3.15 (m, 5H), 2.18–2.12 (m, 3H), 1.76–1.51
(m, 6H), 1.37–1.28 (m, 2H), 1.14–1.05 (m, 6H), 0.88 (s, 3H), 0.76 (s,
3H) ppm. 13C-NMR (75MHz, acetone-d6): d¼ 176.8, 171.5, 144.3,
141.6, 136.1, 126.6, 124.6, 118.6, 75.6, 50.7, 50.5, 49.8, 46.5, 38.1,
35.6, 34.9, 31.1, 30.9, 28.6, 27.5, 26.6, 24.5, 22.2, 21.98, 21.3,
18.9 ppm. HRMS (ESI): m/z Calcd for C26H38NO7S2 [MþH]þ:
540.2090; found 540.2080.
N-[3-(allyldisulfanyl)propanoyl]rosmaricine (32)
The green oil was crystallised with diethyl ether and rinsed with
the same solvent for three times to provide 15mg of pure prod-
uct. Moreover, the liquid filtrate was purified by CC (silica gel;
CH2Cl2/MeOH; in gradient up to 99.6:0.4). The fractions containing
the purified product were gathered up to provide the final prod-
uct as a light green-olive solid. Yield: 24%. Melting point
206.9–209.2 C. 1H-NMR (300MHz, acetone-d6): d¼ 8.57 (br s, 1H,
NH collapsed with D2O), 8.26 (br s, 2H, OH collapsed with D2O),
6.74 (s, 1H, ArH), 5.92–5.83 (m, 1H), 5.21–5.10 (m, 2H), 5.04 (t, 1H,
J¼ 3.6 Hz), 4.57 (d, 1H, J¼ 3.6 Hz), 3.40 (d, 2H, J¼ 7.2 Hz), 3.33–3.10
(m, 3H), 3.03 (t, 2H, J¼ 6.3 Hz), 2.67 (t, 2H, J¼ 6.2 Hz), 2.08 (s, 1H),
2.03–1.87 (m, 1H), 1.57–1.43 (m, 3H), 1.22–1.14 (m, 6H), 1.00 (s,
3H), 0.88 (s, 3H) ppm. 13C-NMR (75MHz, acetone-d6): d¼ 176.8,
169.9, 144.3, 141.6, 136.0, 133.6, 126.4, 124.2, 118.7, 117.8, 75.6,
50.7, 50.6, 46.5, 41.5, 38.1, 35.1, 34.0, 31.1, 30.9, 27.5, 26.6, 22.2,
21.9, 21.3, 18.9 ppm. HRMS (ESI): m/z Calcd for C26H36NO5S2
[MþH]þ: 506.2035; found 506.2026.
N-[4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoyl]rosmaricine (33)
The crude residue was crystallised with a solution of ethyl acetate/
diethyl ether (1:3). The resulting orange solid was purified by CC
(silica gel; CH2Cl2/MeOH; in gradient up to 99:1). The fractions con-
taining the purified product were rounded up and firstly crystal-
lised with few drops of ethyl acetate and a solution of diethyl
ether/petroleum ether (1:1). The solid was rinsed with diethyl
ether/petroleum ether (1:1) to get orange crystals corresponding
to the desired product. Yield: 19%. Melting point 243.2–249.7 C.
1H-NMR (300MHz, acetone-d6): d¼ 9.12 (s, 1H), 8.04 (d, 2H,
J¼ 7.4 Hz), 7.72 (d, 2H, J¼ 7.4 Hz), 6.82 (s, 1H), 5.28 (s, 1H), 4.72 (s,
1H), 3.50–3.20 (m, 2H), 1.70–1.35 (m, 4H), 1.35–1.05 (m, 8H), 0.99
(s, 3H), 0.92 (s, 3H) ppm. 13C-NMR (75MHz, DMSO-d6): d¼ 214.0
177.8, 166.2, 160.35, 156.1, 147.6, 145.2, 142.6, 136.8, 129.2, 128.2,
127.8, 127.5, 126.0, 124.5, 118.4, 76.3, 60.2, 50.9, 49.9, 46.6, 38.2,
31.4, 26.6, 2.1, 22.8, 21.9, 19.2 ppm. HRMS (ESI): m/z Calcd for
C30H32NO5S3 [MþH]þ: 582.1443; found 582.1447.
STAT AlphaScreen-based assay
STAT3 inhibitory activity of the described compounds was tested
by the AlphaScreen-based assay to evaluate the potential inhib-
ition of the interaction between STAT3-SH2 domain and pTyr-con-
taining peptides according to the previously reported procedure54.
For the most interesting compounds, selectivity tests versus STAT1
were performed.
Luciferase reported promoter activities assay
To measure the NF-jB promoter activity, HCT-116 cells were
seeded in 100mm dish and transiently transfected with 6lg of
DNA (NF-jB plasmid, containing luciferase reporter gene57 with
turbofect reagent (Carlo Erba Reagents). After 24 h, cells were
seeded in 48-well plates (40.000 cells per well). On the next day,
cells were incubated with our compounds for 2 h (pre-treatment)
and then TNF-a was added in every well at (10 ng/ml). After 5–6 h,
luciferase activity was measured by using Neolite reagent
(PerkinElmer Life Sciences, Waltham, MA) according to the man-
ufacturer’s instructions58.
STAT3 luciferase reporter gene assay
STAT3 reporter HeLa stable cell lines (Signosis Inc, Santa Clara, CA)
were incubated in a 96-well microplate for 24 h. Cells were pre-
treated with test compounds for 2 h, and 10 ng/ml (w/v) of
Scheme 5. Reagents and conditions: (a) ROH (6, 9, 11), EDAC, HOBt, DIPEA, anh. DMF, r.t., 2–6 h.
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oncostatin M were applied and incubated for 4 h. Cells were washed
with medium not supplemented with phenol red, and Steady-GloVR
reagent (Promega, Madison, WI) was applied. After 15min incuba-
tion, the signals were detected by ARVO Light 1420 (PerkinElmer
Life Sciences, Waltham, MA). The relative signal intensity was calcu-
lated in each well as the ratio for the mean signal of vehicle.
MTT-assay
Following the same protocol used for previous cytotoxicity assays
by N. Ferri55, cells were seeded in 48-well plate (40.000 cells/well)
and, after 24 h, they were incubated with different concentrations
of our compounds for 48 h.
The determination of the conversion of MTT (3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) to formazan was
determined by using a commercially available kit (Millipore,
Billerica, MA), according to the manufacturer’s instructions.
Results and discussion
Synthesis
Six sulfurated moieties were previously described, and were pre-
pared accordingly: 159, 360, 561, 662, 963, 1163. The alcohols 2 and
4 were synthesised according to Scheme 1.
The methyl esters 7 and 10 were obtained in good yields,
through the condensation of the carboxylic acids 6 and 9 with
methanol, using DCC and DMAP as coupling agents. Finally, the
sulfone 8 was prepared by reacting sodium methanesulfinate with
5-bromovaleric acid (Scheme 1).
Ferulic acid hybrids have been obtained by coupling the MEM-
protected acid (35) with the proper alcohols (S-2-hydroxyethyl
methanesulfonothioate (1), S-4-hydroxybutyl methanesulfono-
thioate (2), 2-(allyldisulfanyl)ethanol (4)), with the S-2-aminoethyl
methanesulfonothioate (3) and with 5-(4-hydroxyphenyl)-1,2-
dithiol-3-thione (5) to achieve the intermediates 36–40. After
deprotection with trifluoroacetic acid (TFA) at r.t., the final com-
pounds (14–18) were obtained (Scheme 2).
Caffeic acid hybrids were obtained through a similar synthetic
route. However, in this case, the protection of the catechol group
was better achieved by treating caffeic acid methyl ester (20) with
NaH and then with MEM-Cl. After 5 N NaOH hydrolysis, the
obtained protected acid (42) was coupled with the sulfurated moi-
eties 1 and 3–5 to achieve the intermediates 28, 29, 43 and 44
and finally, the treatment with TFA at r.t. gave the expected
hybrids 21–24 (Scheme 3).
To be noted that, during the coupling reaction between com-
pound 42 and 2-(allyldisulfanyl)ethanol (4) and in a lower extent
with 1, the formation of the N-acylurea (45) of the acid was
observed (Figure 4).
Compounds 25–27 were synthesised by coupling the S-2-
hydroxyethyl methanesulfonothioate (1) with cinnamic acid, 3,4-
dichlorocinnamic and 3,4-dimethoxycinnamic acid, respectively
(Scheme 4).
Finally, rosmaricine (30) was acylated with the sulfurated acids
6, 9, and 11, in presence of EDAC and HOBt as coupling reagents,
according to Scheme 5.
Biological results
The new sulfurated-drug hybrids, together with their parent com-
pounds have been submitted to the AlphaScreen-based assay, to
investigate their ability to bind STAT3 directly, through the evalu-
ation of the inhibition of the binding of SH2-containing proteins
to their correspondent phosphopeptides, the physiological ligands.
Moreover, in order to check the selectivity of action of our mole-
cules on STAT3, their ability to interact with SH2-domain of STAT1,
a family member protein exhibiting a high degree of sequence
homology to STAT3 and tumor suppressive properties in many
systems, has also been tested. Results, expressed as % of protein
inhibition at 30lM or as IC50 (lM), are reported in Tables 1 and 2,
together with the cytotoxic activity on HCT-116 cell line (MTT
assay) expressed as IC50 (lM). Since AlphaScreen is a cell-free
assay, not always there is a correspondence between the potency
Table 1. Biological activities of sulfurated parent compounds (1–6, 9, and 11) and some related compounds (7, 8, and 10).
AlphaScreen Assay STAT3 reporter
assay
NF-jB promoter
assay Cytotoxicity
Compd
STAT3 %
inhibition ± SD
at 30 lM
STAT3
IC50 ±SD (lM)
STAT1 %
inhibition ± SD
at 30 lM
STAT1
IC50 ±SD (lM)
(HeLa)
IC50±SD (lM)
(HCT-116)
IC50 ±SD (lM)
(HCT-116)
IC50 ±SD (lM)
1 11.6a >30 n.t. n.t. n.t NA NA
2 88.4 ± 0.5 4.4 ± 0.3 73.7 ± 1.4 8.6 ± 0.7 n.t n.t. NA
3 10.2b >30 n.t. >3c n.t n.t. NA
4 55.7 ± 2.5 22.2 ± 3.0 11.7 ± 6.0 >30 n.t n.t. NA
5 43.7a >30 n.t. n.t. n.t 36.7 ± 11.4 71.2 ± 15.0
6 72.5 ± 4.8 4.7 ± 1.1 n.t. >3d n.t. NA NA
7 99.6 ± 0.1 1.9 ± 0.2 70.8 ± 1.2 20.1 ± 0.4 n.t. n.t. NA
8 3.8 ± 2.8 >30 n.t. n.t. n.t. n.t. NA
9 43.9 ± 3.6 >30 n.t. n.t. n.t. n.t. NA
10 42.0 ± 4.7 >30 11.2 >30 n.t. n.t. NA
11 1.2 ± 6.0 >100 n.t. n.t. >100 NA NA
n.t.¼ not tested.
NA¼ not active up to 100 lM.
aMean of two experiment.
bInhibition at 3 lM: 46.8 ± 10.1%.
cInhibition at 3 lM: 14.5 ± 7.1%.
dInhibition at 3lM: 8.6 ± 1.7%.
Figure 4. Structure of compound 45.
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of STAT3 inhibition and cytotoxicity, probably due to not optimal
physicochemical properties of the tested compounds, such as
solubility and chemical stability in the culture medium and cell
permeation. For this reason, compounds which exhibited antiproli-
ferative activity, were also evaluated for their ability to inhibit
STAT3 reporter activity on cells (HeLa). Results, expressed as IC50
(lM), are reported in Tables 1 and 2. In addition, the ability of the
most active compounds to inhibit the promoter activity of NF-jB
on HCT-116 cells was also investigated (Luciferase assay) and it is
reported as IC50 (lM) in the same tables.
First of all, it is observed that among the sulfurated moieties,
that were used to form the conjugated molecules, only three of
them (2, 4, and 6) exhibited IC50< 30 lM for the binding to
STAT3-SH2 domain (AlphaScreen assay) (Table 1). Particularly, (4-
methanesulfonylthio)butanol (2) was more active than the lower
homolog 2-(methanesulfonylthio)ethanol (1), as the methyl ester 7
exhibited a higher activity than the corresponding free acid 6.
Thus, the binding activity seems somewhat increasing with the
increasing lipophilicity of the molecule; this observation holds also
for the feruloyl esters 15 and 14 of the two homologous alcohols
2 and 1, respectively. However, no difference was observed
between ester 10 in comparison to free acid 9.
The replacement of the thiosulfonate function in compound 6
(IC50¼ 4.7 lM) with a sulfone group (compound 8) led to the loss
of activity on STAT3. Thus, the methanethiosulfonate moiety is
confirmed as crucial for the inhibitory activity, probably through
the interaction with the thiol group of cysteines in STAT3.
The same set of compounds did not display any cytotoxicity
versus the HCT-116 cancer cells up to 100 lM concentration, with
the only exception of 4-hydroxyphenyldithiolethione (5)
(IC50¼ 71.2 lM).
Also, the phenolic parent compounds, ferulic (12) and caffeic
(19) acids and their simple methyl esters (13 and 20) did not
bind, at least up to 30 lM concentration, to STAT3-SH2 domain
(Table 2), confirming that they are not "direct" STAT3 inhibitors
and that they may act on other steps of STAT3 pathway.
Very interestingly, all the sulfurated hybrid molecules derived
from ferulic acid (14–18), caffeic acid (21–24) and from other cin-
namic acids (25–29) (rosmaricine derivatives will be discussed
later) were able to strongly bind STAT3-SH2 domain. Some of
them were also able to inibit the NF-jB transcriptional activity in
HCT-116 cells and STAT3 reporter activity in HeLa cells.
Accordingly, six hybrid compounds inhibited HCT-116 cell prolifer-
ation in vitro, with IC50 in the range 47–123 lM. The inhibition of
both transcription factors exerted by esters 14, 15, 21, 23, and 24
in cell assays and their antiproliferative activity versus HCT-116
cells indicate that the ester function may survive to the action of
cellular esterases and to the deactivating power of GSH that is
commonly overexpressed in cancer cells. In particular, the hybrid
molecules containing the thiosulfonate function exhibited IC50 in
the range 0.3–1.8lM. These compounds were also rather selective
STAT3 inhibitors in comparison to STAT1, in spite of the high
degree (78%) of sequence homology that characterises the two
proteins, and exhibited a higher selectivity index (S.I.¼ IC50 STAT3/
IC50 STAT1: range 6–33, plus an outranging value of ~70) in com-
parison to the previously described42,43 thiosulfonate hybrid a–i
(S.I: in the range 2–12, plus an outranging value of 43).
The IC50 values for the inhibition of STAT3 and STAT1 of the
thiosulfonate subset of compounds (but also for other subsets)
did not run parallel, indicating that the structural and physico-
chemical requirements to hit the two proteins are rather different;
particularly it is observed that the two potent STAT3 inhibitors 15
and 26 were only moderately selective (S.I.¼ 6 and 6.3, respect-
ively), but the other potent STAT3 inhibitor 27 was 10-fold more
selective (S.I.¼ 69.7).
Although, the real mechanism has not been elucidated yet, it is
possible that methanethiosulfonates covalently modify STAT3 cys-
teines and that these structural changes lead to altered STAT3
Table 2. Biological activities of parent compounds (ferulic acid 12, caffeic acid 19, and rosmaricine) and their sulfurated derivatives.
AlphaScreen Assay STAT3 reporter
assay
NF-jB promoter
assay Cytotoxicity
Compd
STAT3 %
inhibition ± SD
at 30 lM
STAT3
IC50±SD (lM)
STAT1 %
inhibition ± SD
at 30 lM
STAT1 IC50 ±SD
(lM)
(HeLa)
IC50 ±SD (lM)
(HCT-116)
IC50 ±SD (lM)
(HCT-116)
IC50 ±SD (lM)
12 0.2 ± 8.2 >30 n.t. n.t. n.t. NA NA
13 2.1 ± 2.3 >30 n.t. n.t. n.t. n.t. NA
14 110.1 ± 0.2 0.9 ± 0.0 110.5 ± 0.6 7.0 ± 0.7 65.4 ± 1.0 116.3 ± 2.9 50.4 ± 5.9
15 100.0 ± 0.1 0.3 ± 0.0 86.0 ± 6.7 1.8 ± 0.4 57.5 ± 1.1 94.0 ± 4.6 64.4 ± 9.1
16 107.8 ± 0.1 1.8 ± 0.5 4.1 ± 5.4 >30 n.t n.t NA
17 67.9 ± 0.8 7.8 ± 0.6 12.0 ± 4.7 >30 n.t n.t. NA
18 51.3 ± 0.7 28.5 ± 0.7 44.2 ± 1.9 >30 n.t NA NA
19 11.0 ± 5.4a >30 n.t. n.t. n.t NA NA
20 12.8 ± 1.1 >30 n.t. n.t. n.t n.t. 90.8b
21 100.1 ± 0.1 0.8 ± 0.2 85.7 ± 4.3 17.0 ± 1.2 60.6 ± 2.8 127.8 ± 8.9 123.2 ± 17.3
22 99.8 ± 0.1 0.9 ± 0.1 17.8 ± 0.3 >30 n.t. n.t. NA
23 70.0 ± 1.7 5.5 ± 0.2 37.7 ± 7.5 >30 94.4 ± 26.1 163.3 ± 11.1 73.0 ± 8.0
24 66.7 ± 0.5 13.2 ± 0.9 21.5 ± 1.8 >30 40.0 ± 1.5 40.6 ± 3.0 46.7 ± 4.1
25 100.0 ± 0.0 0.5 ± 0.0 100.3 ± 0.2 3.6 ± 0.4 72.5 ± 4.4 NA 95.2 ± 8.9
26 100.0 ± 0.1 0.3 ± 0.0 103.8 ± 1.7 1.9 ± 0.2 n.t n.t. NA
27 99.7 ± 0.1 0.3 ± 0.0 68.9 ± 10.2 20.9 ± 4.9 n.t n.t. NA
28 100.0 ± 0.1 0.6 ± 0.1 98.4 ± 0.9 6.3 ± 0.5 n.t n.t. NA
29 100.1 ± 0.1 1.1 ± 0.0 63.3 ± 0.5 19.5 ± 0.3 n.t n.t. n.t.
30 99.7 ± 0.0 1.9 ± 0.1 91.8b 10.0 ± 0.6 42.4 ± 2.4 43.4 ± 6.9 65.2 ± 2.3
31 100.1 ± 0.1 0.2 ± 0.0 99.9 ± 0.3 2.8 ± 0.1 >100 53.3 ± 10.9 73.8 ± 0.9
32 99.5 ± 0.0 2.3 ± 0.4 23.9 ± 0.4 >30 37.0 ± 0.8 13.0 ± 0.7 3.5 ± 2.8
33 94.5 ± 0.4 2.9 ± 0.2 58.8 ± 5.9 19.7 ± 4.0 >100 73.0 ± 13.2 65.4 ± 3.9
n.t.¼ not tested.
NA¼ not active up to 100 lM.
aInhibition at 300 lM: 61.8 ± 2.5%.
bMean of two experiments.
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signaling. Such kind of STAT3 inhibition would be challenging
because healthy cells could also be affected. However, as the
above hybrid molecules were able to discriminate between the
two STAT proteins, they might also display an acceptable selectiv-
ity versus the cysteine-containing proteins of the healthy cells.
The activities of the unsubstituted cinnamic ester (25) and the
non-phenolic 3,4-disubstituted cinnamic esters (26–28) and amide
(29) are comparable to those of the ferulic and caffeic esters and
amides (14–16, 21, 22), suggesting that the phenolic function
(and the related anti-oxidant activity) is not essential for a valid
inhibitory activity on STAT proteins, while it might profitably
address the molecules to other relevant targets, eventually concur-
ring to the antiproliferative activity (as for compounds 23 and 24).
Moreover, it is not excluded that some contribution to the
binding capability, mostly related to the sulfurated moieties, could
derive from the Michael addition propensity of the carbonyl-conju-
gated double bond66.
The STAT3 inhibitory activities of the variously substituted cin-
namic esters were confined within a rather narrow range (IC50
from 0.3lM to 0.9lM), that includes also the IC50 value (0.7lM)
of the corresponding ester of the non-aromatic valproic acid (a)
previously described. Therefore, a further extension of the present
exploratory study to other esters of aromatic and aliphatic acids
with methanesulfonylthio-ethanol and –butanol is worthy to be
pursued.
The simple esterification of ferulic and caffeic acids with metha-
nol, while surely increasing the molecular lipophilicity, did not
apparently improved their poor STAT3 inhibitory activity; neverthe-
less, some increase of cytotoxicity was observed in the case of caf-
feic acid methyl ester 20 (IC50¼90.8lM), in line with the
previously observed increase of cytotoxicity in the phenylethyl and
phenylpropyl esters of caffeic acid28.
As far as allyldisulfide derivatives, they seem to interact in a
weaker way than methanethiosulfonates with the STAT3-SH2
domain. Nevertheless, the caffeic acid derivative 23, besides STAT3
inhibition (IC50¼ 5.5lM), showed also moderate NF-jB inhibitory
activity and antiproliferative activity on HCT-116 cells
(IC50¼73.0lM); thus, exhibiting interesting properties to be further
investigated for a potential multi-target anticancer activity.
Dithiolethione drug hybrids 18 and 24 were the weakest and
less selective inhibitors on STAT3-SH2 domain compared to the
corresponding methanethiosulfonate and allyldisulfide derivatives
in the AlphaScreen-based assay; however, the caffeic acid deriva-
tive 24, exhibited a very good profile, inhibiting both the tran-
scription factors (STAT3 AlphaScreen: IC50¼ 13.2 lM; STAT3
reporter assay: IC50¼ 40.0 lM and NF-jB promoter activity:
IC50¼ 40.6lM) and the HCT-116 cell proliferation (IC50¼ 46.73lM)
at comparable concentrations.
Of particular interest were the results of the testing of rosmari-
cine (30) and of its amidic derivatives (31–33) of sulfurated acids,
namely 5-(methanesulfonylthio)pentanoic acid (6), 3-(allyldisulfa-
nyl)propionic acid (9), and 4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoic
acid (11).
First of all, it is observed that rosmaricine itself was able to
strongly bind to the STAT3-SH2 domain (IC50¼ 1.9lM) and to
inhibit STAT3 reporter activity in HeLa cells, as well as NF-jB tran-
scriptional activity in HCT-116 cells; thus, exerting a moderate anti-
proliferative activity (IC50¼ 65 lM) against the same cancer cells.
The amidification of rosmaricine with the methanesulfonylthio-
pentanoic acid (31) produced a 10-fold increase of inhibitory
potency on STAT3 (IC50¼ 0.2lM), while the linkage with the allyl-
disulfanyl and the dithiolethione moieties left unchanged or even
slightly reduced the rosmaricine activity on STAT3. Thus, once
more, the thiosulfonate moiety resulted the most potent enhacer
for the binding to STAT3-SH2 domain, while the other relevant
parameters were affected in different directions and degree.
Indeed, the hybrids 31 and 33, despite the different IC50s ver-
sus STAT3 (0.2 and 2,9lM, respectively), exhibited a quite reduced
STAT3 reporter activity, but unchanged activity versus NF-jB and
unchanged cytotoxicity in comparison to the parent rosmaricine.
On the contrary, the 3-(allyldisulfanyl)propanoyl derivative 32
exhibited an unchanged STAT3 reporter activity, in comparison to
rosmaricine, but an increased potency versus the NF-jB transcrip-
tion factor and a 19-fold increase of antiproliferative activity
(IC50¼ 3.5lM). Versus the normal human smooth muscle cells
(hSMC), compound 32 exhibited an IC50¼ 21.2lM, with a selectiv-
ity index of 6. The valuable cytotoxicity of 32 on HCT-116 cells,
was confirmed, even at lower level against MCF-7 (hormone sensi-
tive breast cancer) cells.
Soon after its first isolation, rosmaricine was investigated for
anticancer activity by Russian authors, but results were not illus-
trated in the only available scanty Chemical Abstracts report67. On
the other hand, rosmaricine and some derivatives53, where the
cathecol groups were either free or methylated resulted inactive
or endowed with borderline activity against the lymphocytic leu-
kemia P388, when injected i.p. in mice, 24 h after the tumor
implants (data from National Cancer Institute, Bethesda, MD).
More recently, by virtual screening and docking studies of
thousands of compounds68, rosmaricine (as well as emetine and
two esters of caffeic and ferulic acids) was suggested as potential
strong inhibitors of epidermal growth factor receptor (EGFR).
Indeed, some natural molecules closely related to rosmaricine, as
carnosic acid, carnosol, and rosmanol, have been shown to pos-
sess antiproliferative activity on a variety of cancer cell lines, and
their activity is mainly related to generation of ROS and inactiva-
tion of STAT348–50.
Thus, the same factors may explain the present observed anti-
proliferative activity on HCT-116 cells of rosmaricine and its deriva-
tives 31 and 33, while the outstanding cytotoxicity of 32 might
be related to the additional interaction of its allyldisulfanyl moiety
with NF-jB moiety and/or other targets.
All these data underline the interesting activity profiles of ros-
maricine and its derivatives (in particular compound 32), which
are worthy of further investigation as potential multi-target anti-
proliferative agents.
Conclusions
Starting from some cinnamic acids (particularly ferulic and caffeic)
and the diterpenoid rosmaricine, 17 new sulfurated hybrid mole-
cules were synthesised and their ability to in vitro inhibit STAT3
and NF-jB transcription factors as well as their cytotoxicity on the
human colon carcinoma cell line (HCT-116) were evaluated.
All resulted hybrid compounds were able to directly and
strongly inhibit STAT3 transcription factor (AlphaScreen assay) and
most of them were also shown to inhibit NF-jB transcriptional
activity in HCT-116 cells and the proliferation of the said cancer
cells. Thus, once more, the conjugation of molecules, each
endowed with even weak affinity versus STAT3 and/or NF-jB tran-
scription factors, produced strong inhibitors of the latter factors,
which (besides the other peculiarities of each moiety) gave rise to
valuable antiproliferative activity on HCT-116 cancer cells.
STAT3 was more potently inhibited in comparison to STAT1, in
spite of the high sequence homology between the two proteins,
indicating the possibility to discriminate among thiol containing
proteins and eventually to achieve novel hybrid compounds able
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 1025
to strongly hit the STAT3 factor with only modest involvement of
healthy cell proteins.
In particular, the methanethiosulfonate drug hybrids interact
with STAT3-SH2 domain more potently than the corresponding
allyldisulfide and dithiolethione derivatives.
The parent compounds were completely devoid of inhibitory
activity at the tested concentrations, or, in a few cases (2, 4, and
6) their potency was quite lower than that of the hybrids, exclud-
ing the observed activity of the latter could be related to the
hydrolytic liberation of the former.
In spite of the very good STAT3 inhibition resulting from the
AlphaScreen assay, only nine compounds exhibited cytotoxicity on
colon cancer cells and inhibition of STAT3 reporter gene activity,
probably due to unsuitable physicochemical properties of some of
the tested compounds, which need to be further investigated and
optimised.
Eight hybrids (14, 15, 21, 23–25, 31, and 33) and rosmaricine
(30) exhibited moderate cytotoxicity, with IC50 in the range
46.7–123.2 lM, but the hybrid 32 (N-(3-allyldisulfanyl)propanoyl-
rosmaricine) displayed a valuable cytotoxicity (IC50¼ 3.5lM), that
was confirmed at lower level, in MCT-7 breast cancer cells.
On the whole, the most interesting compounds were the two
thiosulfonate-ferulic acid hybrids (14 and 15), the allyldisulfide-caf-
feic acid hybrid (23), the dithiolethione-caffeic acid hybrid (24),
and the foresaid rosmaricine hybrid (32), besides rosmaricine (30)
itself. All of them inhibited both STAT3 and NF-jB transcription
factors and exhibited from moderate to good antiproliferative
activity and may represent hit compounds for developing multi-
target anticancer agents.
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